NCT00260689View on ClinicalTrials.gov

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

November 28, 2005

Primary Completion Date

May 4, 2016

Study Completion Date

May 4, 2016

Conditions
ImmunosuppresionThrombocytopeniaPancytopeniaNeutropenia
Interventions
BIOLOGICAL

Anti-thymocyte globulin (rabbit)

BIOLOGICAL

Anti-thymocyte globulin (horse)

DRUG

Cyclosporine

DRUG

Alemtuzumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00260689 - Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter